ArticleCancer immunology, immunotherapy : CII2026
GFI1 enhances MHC-I expression in tumor cells and augments tumor responsiveness to PD-1/PD-L1 inhibitors.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundGrowth factor-independent-1 transcription repressor (GFI1) is crucial for determining the differentiation and fate of exhausted CD8
methodsThe tumor cell-intrinsic expression of GFI1 was examined via RT‒qPCR and Western blotting. Immunohistochemical staining of tumor tissues was performed to assess the relationships among GFI1, CD8, and MHC I expression. A syngeneic mouse model and clinical tumor samples from NSCLC patients undergoing immunochemotherapy were used to evaluate how tumor cell-intrinsic GFI1 affects the response to immunotherapy. Additionally, techniques such as flow cytometry, immunoprecipitation, ChIP-qPCR, immunofluorescence, and both loss- and gain-of-function approaches were employed to investigate the underlying mechanisms involved.
resultsTumor-intrinsic GFI1 expression was positively associated with MHC I expression and the infiltration of CD8
conclusionsThis study demonstrated the crucial role of tumor-intrinsic GFI1 in enhancing antitumor immune responses, suggesting a new target for increasing the effectiveness of PD-1/PD-L1 blockade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.